AU2021294796B2 — Salt of compound and pharmaceutical composition containing salt
Assigned to Shenzhen Forward Pharmaceuticals Co Ltd · Expires 2025-05-29 · 1y expired
What this patent protects
The present invention relates to a salt formed by a compound of formula (I) and an acid. The acid is selected from hydrochloric acid, methanesulfonic acid, benzenesulfonic acid, ethanesulfonic acid, maleic acid, hydrobromic acid, citric acid, L-tartaric acid, and p-toluenesulfoni…
USPTO Abstract
The present invention relates to a salt formed by a compound of formula (I) and an acid. The acid is selected from hydrochloric acid, methanesulfonic acid, benzenesulfonic acid, ethanesulfonic acid, maleic acid, hydrobromic acid, citric acid, L-tartaric acid, and p-toluenesulfonic acid. The present invention also relates to a method for treating non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation by means of using the salt.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.